We assessed bone health in over 2500 adults with diabetes across Türkiye. T1DM patients had lower BMD, while T2DM patients showed higher fracture risk despite higher BMD. Several modifiable factors were linked to osteoporosis. These findings support personalized bone assessments in diabetic populations. Diabetes mellitus (DM) is a recognized risk factor for bone fragility. While type 1 DM (T1DM) is typically associated with low bone mineral density (BMD), type 2 DM (T2DM) often presents with higher BMD despite increased fracture risk. Large-scale comparative studies remain limited. To evaluate bone health, including osteopenia, osteoporosis, and fracture risk, in adults with T1DM and T2DM. This multicenter, cross-sectional study included 2562 patients (224 with T1DM, 2338 with T2DM) from 27 centers across Türkiye. BMD was assessed using dual-energy X-ray absorptiometry (DXA) and fracture risk was estimated via the Turkish-adapted FRAX® algorithm in patients aged ≥ 40 years. Multinomial logistic regression was used to identify independent predictors of low BMD. Osteoporosis prevalence was 5.5

Background: The objective of this study was to compare the effects of bisphosphonates and denosumab on sarcopenia-related parameters, contributing to a better understanding of osteosarcopenia management. Methods: This cross-sectional, comparative study assessed physical performance, muscle strength, muscle mass, and sarcopenia category in postmenopausal women aged 65 to 80 years with osteoporosis who were receiving either bisphosphonates or denosumab. Additional groups consisted of untreated osteoporotic patients and controls without osteoporosis (n = 50 per group). Muscle mass was assessed using bioelectrical impedance analysis, and the classification of sarcopenia was assessed according to the EWGSOP2 criteria. Results: Among the osteoporotic groups, the 4 m walking speed, 5-chair stand test, and timed up-and-go performance did not differ significantly, although denosumab-treated patients had numerically shorter completion times. Nondominant handgrip strength was the only grip parameter showing a significant between-group difference (p = 0.026), mainly due to higher values in denosumab-treated patients than in untreated osteoporotic patients; dominant and maximum handgrip strength were comparable. Skeletal muscle mass was higher in the denosumab group than in both the bisphosphonate-treated and untreated osteoporosis groups (p = 0.045), whereas ALM, ASM, and the ASMI did not differ significantly. No statistically significant between-group differences were observed in SARC-F scores or sarcopenia classifications. Controls had significantly higher odds of sarcopenia absence compared with untreated osteoporotic patients, and treatment duration was not correlated with sarcopenia-related parameters. Conclusions: These findings suggest a favorable but limited association between denosumab treatment and selected muscle-related parameters. Prospective longitudinal studies are needed to determine whether anti-osteoporotic therapies influence osteosarcopenia.

Background and Objectives: Pediatric-onset metabolic bone diseases, including osteogenesis imperfecta (OI), hypophosphatemic rickets (XLH), hypoparathyroidism, and McCune–Albright syndrome (MAS), require lifelong follow-up because of persistent skeletal fragility, biochemical abnormalities, and functional morbidity extending into adulthood. However, evidence regarding structured transition from pediatric to adult care in these rare disorders remains limited. This study evaluated one-year outcomes of a multidisciplinary transition program for adolescents and young adults with rare metabolic bone diseases. Materials and Methods: This retrospective cohort study included 20 patients aged ≥17 years who underwent evaluation through a structured transition pathway consisting of multidisciplinary team meetings, a joint pediatric–adult transition clinic, and subsequent follow-up in adult endocrinology. Demographic, clinical, treatment, and transition-related data were extracted from medical records. The primary outcome was successful transition, defined as at least one adult endocrinology visit within 12 months. Secondary outcomes included attendance at the transition clinic, follow-up continuity, and treatment modifications. Results: All patients underwent multidisciplinary evaluation, and 85% attended the joint transition clinic. Successful transfer to adult endocrinology was achieved in 90% (18/20), while regular follow-up during the first year was maintained in 75%. Retention was highest in patients with OI, MAS, XLH, vitamin D-dependent rickets, and DiGeorge syndrome (100%). Greater variability was observed in postoperative and primary hypoparathyroidism. Treatment adjustments were required in 40% of patients, including optimization of phosphate/calcitriol replacement and reassessment of bisphosphonate or burosumab therapy. Three patients were lost to follow-up. No acute transition-related complications were observed. Conclusions: In this small exploratory cohort, implementation of a structured multidisciplinary transition pathway was feasible and was accompanied by high transfer and one-year retention rates. Observed differences across diagnostic subgroups should be interpreted cautiously, and larger multicenter comparative studies are needed to evaluate the effectiveness of structured transition frameworks.

Objective: This study aimed to assess health-related quality of life (HRQoL) and fatigue in patients with osteogenesis imperfecta (OI) and to compare these outcomes with those of healthy controls. In addition, the associations between fatigue and the physical and mental components of HRQoL, as well as related clinical factors, were examined. Method: Between June 2024 and June 2025, 27 adults with OI were enrolled and compared with 27 healthy controls. Fatigue was assessed with the FSS and HRQoL with the SF-36, including PCS and MCS scores. We evaluated factors associated with the PCS and MCS and examined the associations between the PCS/MCS and fatigue. Results: PCS scores were significantly lower in patients with OI types III and IV compared with controls, whereas no difference was observed between type I and controls. No significant differences were found in MCS scores or mental health domains among the groups. Fatigue levels did not differ significantly among the groups. Height was positively correlated with the PCS, while the number of fractures showed a moderate negative correlation. Lower PCS scores were observed in patients with lower extremity deformities and a history of orthopedic surgery. Alendronate use and longer treatment duration showed associations with higher PCS scores. In addition, a significant negative correlation was found between the MCS and fatigue severity. Conclusions: Adults with OI showed impaired physical functioning compared with controls, with relatively preserved mental functioning and similar fatigue levels. Physical functioning was associated with height, fracture burden, orthopedic surgery, and alendronate use, while fatigue was associated with mental functioning, underscoring the need for patient-centered care addressing both skeletal and psychosocial outcomes.

This retrospective study evaluates the impact of the transition council on clinic attendance, glycaemic control and complications in type 1 diabetes. Since 2015, monthly multidisciplinary transition meetings (transition councils) have been held involving paediatric and adult endocrinology departments at Bursa Uludag University Hospital, Turkey. The study retrospectively compared outcomes of type 1 diabetes patients who transitioned to adult care via the council versus standard transition. A total of 180 patients (90 in each group) aged at transition 18–21 years (58.9% male) were included. Within 6 months post-transition, 84.9% of council patients (exposed group) and 54.1% of the standard care group attended at least one visit ( p  < 0.001). Regular follow-up during the first year was significantly higher in the exposed group (58.1% vs. 29.7%, p  < 0.001); rates were similar between groups in subsequent years. HbA1c levels increased significantly 1 year after transition in the standard care group ( p  = 0.025), while the exposed group remained stable ( p  = 0.719). No significant differences were observed in hospitalisation or diabetic ketoacidosis. This transition model may improve regular follow-up rates during the challenging first year of transition and help prevent additional deterioration in glycaemic control compared to standard care. Prospective randomised trials could strengthen these findings.

AIM:This retrospective study evaluates the impact of the transition council on clinic attendance, glycaemic control and complications in type 1 diabetes. METHODS:Since 2015, monthly multidisciplinary transition meetings (transition councils) have been held involving paediatric and adult endocrinology departments at Bursa Uludag University Hospital, Turkey. The study retrospectively compared outcomes of type 1 diabetes patients who transitioned to adult care via the council versus standard transition. A total of 180 patients (90 in each group) aged at transition 18-21 years (58.9% male) were included. RESULTS:Within 6 months post-transition, 84.9% of council patients (exposed group) and 54.1% of the standard care group attended at least one visit (p < 0.001). Regular follow-up during the first year was significantly higher in the exposed group (58.1% vs. 29.7%, p < 0.001); rates were similar between groups in subsequent years. HbA1c levels increased significantly 1 year after transition in the standard care group (p = 0.025), while the exposed group remained stable (p = 0.719). No significant differences were observed in hospitalisation or diabetic ketoacidosis. CONCLUSION:This transition model may improve regular follow-up rates during the challenging first year of transition and help prevent additional deterioration in glycaemic control compared to standard care. Prospective randomised trials could strengthen these findings.

Background:Transition describes preparing children with chronic illnesses for adult healthcare and gradually transferring their care, starting late adolescence. Joint meetings and visits are recommended during this process. This study examines an 8-year transition experience in our clinic, focusing on the differences between adult and pediatric endocrinology practices and the rates of loss to follow-up in specific disease groups. Methods:Three hundred thirty-five patients evaluated in transition meetings were included. The frequency of visits 1 year before transition, during the first and second years after transition, the number of patients lost to follow-up and disease groups were analyzed. Results:Among the patients discussed in the transition meetings, 56.3% participated in joint visits. Post-transition, 82.5% of patients continued their follow-up care, while 17.5% were lost to follow-up. There was a statistically significant difference in the number of visits before and after the first year of transition (P = 0.000). Conclusion:To increase adaptation during the transition, informing patients and families about the process at every visit after late adolescence is beneficial. Moreover, scheduling joint visits on flexible dates and increasing the number of joint visits per patient could substantially enhance patient participation and follow-up rates. We observed that patient follow-up frequency was higher in pediatric endocrinology due to differences in pediatric and internal medicine practices.

In this single-center retrospective study, we aimed to evaluate the results of medical therapy as primary or secondary treatment following surgery and compare follow-up outcomes between the two approaches. Patients were grouped as medical therapy alone (Group M) and surgery plus medical therapy (Group S+M). Patients' demographics, such as age and gender, and age at the diagnosis were recorded. Differences between the pre-and post-treatment tumor size, prolactin (PRL) levels, Knosp grades, tumor response to treatment, improvement in hypofunctions, visual field, and biochemical control were recorded and compared between the two groups. A total of 41 patients diagnosed with giant prolactinomas were included in the study. Hypopituitarism was found in 82.93%, hypogonadism in 80.59%, GH deficiency in 51.22%, ACTH deficiency in 36.59%, and TSH deficiency in 41.46% of the patients. Visual field defects were found by 60.53%. Tumor volume at diagnosis was significantly higher in Group M (p 0.05). This study's results demonstrate no statistically significant difference between medical therapy alone and surgery plus medical therapy regarding the reduction of tumor volume and normalization of PRL values in patients with giant prolactinomas. Surgery should be reserved for severe compression conditions, and potentially unnecessary surgical approaches should be avoided.

Background Thyroid cancer is one of the five most common cancers causing bone metastasis. If there is an increase in serum thyroglobulin-antithyroglobulin levels in differentiated thyroid cancer or calcitonin levels in medullary thyroid cancer, patients should be evaluated for recurrence and distant metastasis. The skeleton is the second most common site of distant metastasis in thyroid cancer after the lung. Bone metastases cause pain, fractures, and spinal cord compression, severely reducing the quality of life. They are associated with poor prognosis. Bone metastases severely reduce the quality of life. This study aimed to retrospectively evaluate the diagnosis and follow-up of patients with thyroid cancer with bone metastases diagnosed at our center. Methodology A total of 1,390 patients diagnosed with thyroid malignancy at our center between 2010 and 2023 were reviewed retrospectively. The study included 27 patients with differentiated and medullary thyroid cancer who had bone metastases. Results Of 27 patients, 19 (70.4%) had differentiated and eight (29.6%) had medullary thyroid cancer. Papillary thyroid cancer constituted 22.2% (n = 6) and follicular thyroid cancer constituted 14.8% (n = 4) of the cases. Papillary carcinoma follicular variant, oncocytic, and poorly differentiated thyroid cancer were diagnosed with similar frequency, each accounting for 11.1% (n = 3). It was found that vertebrae were most commonly involved, followed by the pelvis, sternum, costae, femur and patella, shoulder and humerus, cranium, and scapula. The five-year survival rate was 72%, and the 10-year survival rate was 53%. Conclusions The number of patients with papillary cancer was the highest, but the rate of bone metastases was the lowest in this group. The highest rate of bone metastases was found in patients with poorly differentiated, oncocytic, medullary, follicular, and papillary cancer, respectively. The results obtained in this study reveal the necessity and importance of bone metastasis evaluation in patients with thyroid cancer.

Purpose The patient-reported outcome becomes important to evaluate the situation perceived by the patients and to develop new strategies. This study aims to adapt the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ), which was specially developed for patients with acromegaly, into Turkish by conducting a validity and reliability study. Methods After the translation and back-translation process, Acro-TSQ was filled in by face-to-face interviews with 136 patients diagnosed with acromegaly and currently receiving somatostatin analogue injection therapy. Internal consistency, content validity, construct validity, and reliability of the scale were determined. Results Acro-TSQ had a six-factor structure and explained 77.2% of the total variance in the variable. The Cronbach alpha value calculated for internal reliability showed high internal consistency (Cronbach’s alpha = 0.870). Factor loads of all items were found to be between 0.567 and 0.958. As a result of EFA analysis, one item fell into a different factor in the Turkish version of the Acro-TSQ, different from its original form. CFA analysis shows that acceptable fit values are obtained for fit indices. Conclusion The Acro-TSQ, a patient-reported outcome tool, shows good internal consistency, and good reliability, suggesting it is an appropriate assessment tool for patients with acromegaly in the Turkish population.

Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Introduction Insulinomas constituting the most common cause of endogenous hyperinsulinism-related hypoglycemia are neuroendocrine tumors originating from pancreatic beta cells. They are generally benign and solitary lesions. Although most cases are sporadic, multiple endocrine neoplasia (MEN) 1-related patients are also present. Material and Method Thirteen patients followed up in Bursa Uludağ University Medical Faculty Endocrinology and Metabolic diseases clinic between the years 2012 and 2021 were retrospectively evaluated. Demographical, clinical, biochemical, radiological and histopathological data of the patients were assessed. Results Eight of the patients were females, and five were males with an average age of 43±14.9 years. Ten of the patients had sporadic, and three had MEN1 syndrome-related insulinoma. During the prolonged fasting test, the patients had a mean lowest plasma glucose level of 36.4 ± 6.2 mg/dl with a simultaneous mean insulin level of 11.3 (4.4 - 214.1) mIU/L and c-peptide level of 2.8 (0.46-12.8) mcg/L. In preoperative localization studies, a lesion was detected in 11 out of 13 (84.6%) patients with upper abdominal computed tomography (CT) and 6 out of 10 patients (60%) with magnetic resonance imaging (MRI). Six patients had grade 1, and 7 patients had grade 2 neuroendocrine tumor. The whole group's mean lesion diameter was 15 (11-48) mm. The mean patient follow-up duration was 30.5 ± 23 months. Hypoglycemia recurred in none of the patients in the postoperative period, and only two patients (15.4%) developed postoperative diabetes mellitus (DM). Conclusion Preoperative localization rates in insulinomas increased due to non-invasive imaging methods and technological developments in recent years. This will probably cause earlier diagnosis and treatment, and pancreas preserving surgery option will be more available in most insulinoma cases.

Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Background: Therapeutic plasma exchange (TPE) is a treatment method that can be used to provide euthyroidism before permanent treatment in patients with severe thyrotoxicosis, in cases of thyroid storm and in cases where antithyroid drug (ATD) cannot be used due to side effects or ineffectiveness. This study presented our results and experience on TPE in thyrotoxic patients. Material and Methods: The data of 10 patients who underwent plasmapheresis for thyrotoxicosis in Bursa Uludag University Faculty of Medicine Endocrinology Clinic were retrospectively analyzed and compared with the literature. Results: Ten patients, 6 female and 4 male, were included. The cause of hyperthyroidism was Graves’ disease in 8 patients and toxic multinodular goiter (TMNG) in 2 patients. It was observed that the reason for applying plasmapheresis in the patients was primarily due to toxic hepatitis. The mean number of plasmapheresis required to maintain euthyroidism was 4 (1-8). While no difference was found between the thyroid-stimulating hormone (TSH) results before and after TPE, free T4 (fT4) and free T3 (fT3) values were statistically significantly lower after TPE. It was observed that the leukocytes were considerably higher after TPE and the sodium and calcium values were markedly lower after TPE in the patients. After TPE, 7 patients underwent total thyroidectomy, 1 patient received radioactive iodine (RAI) treatment, and 2 were discharged with ATD treatment. Conclusions: TPE is an effective and safe treatment option that can be applied in cases where it is necessary to provide rapid euthyroidism before permanent treatments or non-thyroid surgical procedures or to treat life-threatening thyrotoxicosis. It requires experience in application and follow-up and provides rapid euthyroidism when performed in experienced centres.